Literature DB >> 23624956

Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.

Andreas Kronbichler1, Paul König, Martin Busch, Gunter Wolf, Gert Mayer, Michael Rudnicki.   

Abstract

BACKGROUND: Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are common causes of nephrotic syndrome in children and adults. However, frequent relapses, steroid dependence, steroid resistance, and side effects of immunosuppressive therapy remain a therapeutic challenge. Rituximab (RTX) has evolved as an efficacious alternative in childhood MCD/FSGS. We report the effect of RTX in 5 adult patients with multirelapsing/steroid-dependent nephrotic syndrome due to MCD or FSGS.
RESULTS: All five patients treated with RTX achieved sustained complete remission and additional immunosuppression was withdrawn. One patient had a relapse after 23 months, which was successfully treated with a further series of RTX infusion without reinitiation of steroid therapy. Serious adverse events related to RTX therapy were not observed in our patients.
CONCLUSIONS: Our results indicate that RTX is effective and cessation of additional immunosuppressants could be achieved in all patients reported in this study. RTX may be an effective alternative therapy in adult patients with multirelapsing/steroid-dependent nephrotic syndrome due to MCD or FSGS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23624956     DOI: 10.1007/s00508-013-0366-7

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  28 in total

1.  Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome.

Authors:  Markus J Kemper; Jutta Gellermann; Sandra Habbig; Rafael T Krmar; Katalin Dittrich; Therese Jungraithmayr; Lars Pape; Ludwig Patzer; Heiko Billing; Lutz Weber; Martin Pohl; Katrin Rosenthal; Anne Rosahl; Dirk E Mueller-Wiefel; Jörg Dötsch
Journal:  Nephrol Dial Transplant       Date:  2011-11-09       Impact factor: 5.992

Review 2.  Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature.

Authors:  Tuelay Kisner; Volker Burst; Sven Teschner; Thomas Benzing; Christine E Kurschat
Journal:  Nephron Clin Pract       Date:  2012-01-26

3.  Rituximab for steroid-dependent nephrotic syndrome.

Authors:  A Beco; I Castro-Ferreira; L Coentrao; R Neto; S Sampaio; M Pestana
Journal:  Clin Nephrol       Date:  2010-10       Impact factor: 0.975

4.  Rituximab treatment for adult patients with focal segmental glomerulosclerosis.

Authors:  Ayami Ochi; Takashi Takei; Kayu Nakayama; Chihiro Iwasaki; Daigo Kamei; Yuki Tsuruta; Ari Shimizu; Shunji Shiohira; Takahito Moriyama; Mitsuyo Itabashi; Toshio Mochizuki; Keiko Uchida; Ken Tsuchiya; Motoshi Hattori; Kosaku Nitta
Journal:  Intern Med       Date:  2012-04-01       Impact factor: 1.271

Review 5.  Prevention and treatment of systemic glucocorticoid side effects.

Authors:  Siamak Moghadam-Kia; Victoria P Werth
Journal:  Int J Dermatol       Date:  2010-03       Impact factor: 2.736

6.  Effect of single-dose rituximab on primary glomerular diseases.

Authors:  Hidekazu Sugiura; Takashi Takei; Mitsuyo Itabashi; Misao Tsukada; Takahito Moriyama; Chiari Kojima; Toshiharu Shiohira; Ari Shimizu; Yuki Tsuruta; Nobuyuki Amemiya; Tetsuya Ogawa; Keiko Uchida; Ken Tsuchiya; Kosaku Nitta
Journal:  Nephron Clin Pract       Date:  2010-08-06

7.  Depletion of functionally active CD20+ T cells by rituximab treatment.

Authors:  Esther Wilk; Torsten Witte; Nicole Marquardt; Tibor Horvath; Katy Kalippke; Kirsten Scholz; Nadine Wilke; Reinhold E Schmidt; Roland Jacobs
Journal:  Arthritis Rheum       Date:  2009-12

8.  Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome.

Authors:  Noritomo Kurosu; Hidekazu Sugiura; Chihiro Iwasaki; Yukari Asamiya; Chiari Kojima; Takahito Moriyama; Mitsuyo Itabashi; Misao Tsukada; Takashi Takei; Tetsuya Ogawa; Takumi Yoshida; Keiko Uchida; Ken Tsuchiya; Kosaku Nitta
Journal:  Intern Med       Date:  2009-11-02       Impact factor: 1.271

Review 9.  Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis?

Authors:  Alain Y Meyrier
Journal:  Kidney Int       Date:  2009-06-03       Impact factor: 10.612

Review 10.  Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature.

Authors:  Martin Bitzan; Mark Anselmo; Lucy Carpineta
Journal:  Pediatr Pulmonol       Date:  2009-09
View more
  8 in total

1.  Nephrotic syndrome; is rituximab the light at the end of the tunnel in the treatment of adult steroid-dependent minimal change disease and focal segmental glomerulosclerosis?

Authors:  Andreas Kronbichler; Gert Mayer
Journal:  J Nephropathol       Date:  2014-01-01

2.  Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease.

Authors:  Eugenia Papakrivopoulou; Ali M Shendi; Alan D Salama; Maryam Khosravi; John O Connolly; Richard Trompeter
Journal:  Nephrology (Carlton)       Date:  2016-10       Impact factor: 2.506

3.  Rituximab for Adults With Multi-Drug Resistant Focal Segmental Glomerulosclerosis: A Case Series and Review of the Literature.

Authors:  Ellia Zhong; Siavash Ghadiri; Alexander Pai; Judith G Marin; Sean J Barbour
Journal:  Can J Kidney Health Dis       Date:  2022-04-19

Review 4.  Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis.

Authors:  Cheng Xue; Bo Yang; Jing Xu; Chenchen Zhou; Liming Zhang; Xiang Gao; Bing Dai; Shengqiang Yu; Zhiguo Mao; Changlin Mei; Chenggang Xu
Journal:  Clin Kidney J       Date:  2020-11-21

Review 5.  The Evidence-Based Approach to Adult-Onset Idiopathic Nephrotic Syndrome.

Authors:  Pietro A A Canetta; Jai Radhakrishnan
Journal:  Front Pediatr       Date:  2015-09-25       Impact factor: 3.418

6.  A higher frequency of CD4⁺CXCR5⁺ T follicular helper cells in adult patients with minimal change disease.

Authors:  Nan Zhang; Pingwei Zhao; Amrita Shrestha; Li Zhang; Zhihui Qu; Mingyuan Liu; Songling Zhang; Yanfang Jiang
Journal:  Biomed Res Int       Date:  2014-08-27       Impact factor: 3.411

Review 7.  Treatment Strategies of Adult Primary Focal Segmental Glomerulosclerosis: A Systematic Review Focusing on the Last Two Decades.

Authors:  Arno Beer; Gert Mayer; Andreas Kronbichler
Journal:  Biomed Res Int       Date:  2016-04-07       Impact factor: 3.411

Review 8.  Proteinuric Kidney Diseases: A Podocyte's Slit Diaphragm and Cytoskeleton Approach.

Authors:  Samuel Mon-Wei Yu; Pitchaphon Nissaisorakarn; Irma Husain; Belinda Jim
Journal:  Front Med (Lausanne)       Date:  2018-09-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.